




| | | | |
|--------------------------|--|---------------------------|---------------------------|
| | | EMLc | ATC codes: B05BC01 |
| Indication | Cerebral oedema | ICD11 code: 8D50.1 | |
| INN | Mannitol hexantrate | | |
| Medicine type | Chemical agent | | |
| List type | Core (EML) Complementary (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 10% solution ; 20% solution | | |
| EML status history | First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1987 (TRS 770) Changed in 1991 (TRS 825) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Wikipedia | Mannitol  | | |
| DrugBank | Mannitol  | | |

Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee considered that diuretics were essential for use in children in the treatment of ascites, acute or chronic renal failure or acute glomerulonephritis. Nephrotic syndrome oedema responds poorly to diuresis and loop diuretics may be hazardous because patients are often volume depleted despite oedema. The Subcommittee endorsed the inclusion of mannitol on the EMLc but recommended it be listed on the complementary list of the EMLc and be reviewed at the next meeting in light of potential newer diuretic agents.

